In an authoritative intelligence dispatch verified through TechCrunch, significant international developments have emerged regarding Insight Partners’ Devin Parekh on why the firm is diversifying while everyone else bets the farm on OpenAI and Anthropic. Observers across key diplomatic, corporate, and policy corridors are actively parsing the immediate impact, as corroborated by verified wire filings. Insight Partners' Devin Parekh opens up about losing Legora to General Catalyst, why he's fine holding stakes in rival AI labs, and why — even as everyone else piles into OpenAI and Anthropic — his $90 billion firm is deliberately staying diversified. Disrupt 2026: OpenAI, Anthropic, Replit, and more take over 6 industry stages. 25% off tickets now TechCrunch Desktop Logo TechCrunch Mobile Logo LatestStartupsVentureAppleSecurityAIAppsDisrupt 2026 EventsPodcastsNewsletters SearchSubmit Site Search Toggle Mega Menu Toggle Topics Latest Insight Partners’ Devin Parekh on why the firm is diversifying while everyone else bets the farm on OpenAI and Anthropic Connie Loizos 2:30 PM PDT · September 13, 2026 Devin Parekh has co-run the heavyweight investment firm Insight Partners for 26 years. Unlike many VCs who are loud on X and seem to live on podcasts, Parekh and Insight Partners tend to lay low. In this sit-down with TechCrunch at its StrictlyVC event on Thursday night in New York, Parekh was refreshingly candid about some of the firm’s wins (it has led and co-led numerous rounds in Databricks, for example, and owns stakes in OpenAI and Anthropic); the deals it hasn’t won, including buzzy AI legal-tech company Legora; conflicts of interest in venture investing; and why Insight has stuck to a diversified strategy even as VCs have piled into the frontier AI labs. There’s a researcher who’s become the big story of the week — do you think that concerns about AI risk amount to hysteria, or do you have real concerns? Sure, there’s a risk some non-state actor gets access to an open-source model and creates a biological weapon. But there’s an even higher probability we get a massive decrease in the time it takes to develop new drugs and cure diseases. I’ll take that bet. I’m on the board of NYU Langone — what AI is already doing with patient data is amazing. We can look at 50 million patient records and tell someone walking in for something unrelated that they have a 25% chance of a heart attack. Net-net, I think this is highly positive. There are risks, sure, just like there are risks with next-generation drone warfare. Every generation has new risks, and somehow, over time, the world still raises living standards. We’re going to need AI to scale healthcare — the population is aging and there aren’t enough medical professionals to go around.
The underlying catalysts behind these events trace back to evolving structural dynamics across the Tech & AI landscape. Over recent quarters, multilateral authorities and market participants have navigated mounting volatility, heightening the urgency of coordinated responses and policy alignment.
Senior analysts and industry stakeholders underscore that strategic transparency remains paramount. As institutional delegations evaluate risk models and operational contingencies, secondary dispatches indicate that further compliance directives and consultative reviews will be initiated in the coming cycle.
Broader economic and regulatory ramifications are projected to ripple across interconnected regional ecosystems. Market analysts note that supply chains, capital allocations, and policy frameworks must swiftly assimilate these verified updates to insulate against systemic bottlenecks.
The Global Post's editorial desk will continue rigorous monitoring of this developing story, with periodic updates provided as official statements and primary documentation are released by relevant governing bodies.
